The Quality Lowdown: Warning Letters Suggest How The FDA Set Priorities During COVID-19
Executive Summary
Calvin Scott, Acella Pharmaceuticals, Soluciones Cosmeticas and TAKA USA warning letters highlight issues with quality units, process control and specifications.
You may also be interested in...
The Quality Lowdown: Yes, The US FDA Expects You To Heed Import Alerts And Testing Requirements
PCCA repackaged adulterated APIs, Allay failed to understand processes, ShangRao and Mexican firms peddled subpotent, sometimes methanol-tainted ethanol.
The Quality Lowdown: What Happens When The US FDA Must Choose Between Risks
Tuberculosis or cancer, sterility assurance or shortages, the choices come at you fast; Takeda, Wintac, Banco Vida updates.
The Quality Lowdown: COVID-19's Pressures On Drug Quality
Demand surges, supply surges and investigator travel restrictions are forcing FDA to adopt less restrictive regulatory approaches during the pandemic.